Écrit par GlobalData | 13 Février 2018

As part of a growing tradition, the new year coincides with a hike in US drug prices, with more than 30 drugs seeing an increase in price. However, after receiving continued criticism from both the public and politicians, it appears that the industry is sticking within a 10% self-imposed price-hike limit, observes GlobalData, a leading data and analytics company.

This 10% cap appears to...

Écrit par GlobalData | 13 Février 2018

One month into 2018, biotech merger and acquisition (M&A) deal activity has already skyrocketed. Acquisitions from colossal drug makers, Celgene and Sanofi, total more than $26bn combined, and the companies have indicated a focus to expand their oncology and hematology portfolios. Many other large pharma firms are expected to join the race and boost their product portfolios through M&As...

Écrit par GlobalData | 13 Février 2018

Celgene’s recent announcement of the acquisition of Juno Therapeutics has put the company in a good position to be a frontrunner in the chimeric antigen receptor- T cell (CAR-T) space. Celgene stands to benefit from Juno’s expertise and ongoing work into addressing concerns surrounding CAR-T, according to GlobalData, a leading data and analytics company.

In January 2018, Celgene...

Écrit par ANSMM | 13 Février 2018

Actualisation du 12 février 2018 : Rupture des stocks des spécialités dosées à 2,4 MUI


D’ici la fin de la semaine, seule la spécialité Benzathine benzylpenicilline Sandoz 1,2 MUI sera disponible sur le marché français.

Les modalités de mise à disposition et de contingentement des unités de benzathine benzylpénicilline sont maintenues.

Les stocks de la spécialité...